Wen-Yu Lyu

689 total citations · 1 hit paper
13 papers, 416 citations indexed

About

Wen-Yu Lyu is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Wen-Yu Lyu has authored 13 papers receiving a total of 416 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 5 papers in Cancer Research and 4 papers in Oncology. Recurrent topics in Wen-Yu Lyu's work include Ginseng Biological Effects and Applications (3 papers), Ubiquitin and proteasome pathways (3 papers) and Cancer-related molecular mechanisms research (3 papers). Wen-Yu Lyu is often cited by papers focused on Ginseng Biological Effects and Applications (3 papers), Ubiquitin and proteasome pathways (3 papers) and Cancer-related molecular mechanisms research (3 papers). Wen-Yu Lyu collaborates with scholars based in China, Macao and United States. Wen-Yu Lyu's co-authors include Lijuan Deng, Dongmei Zhang, Ming Qi, Minfeng Chen, Qi Qi, Zhe‐Sheng Chen, Jiaxu Chen, Amit K. Tiwari, Wen‐Cai Ye and Jincheng Zhong and has published in prestigious journals such as Free Radical Biology and Medicine, Molecular Cancer and Phytochemistry.

In The Last Decade

Wen-Yu Lyu

12 papers receiving 411 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

m6A modification: recent advances, anticancer targeted drug discovery and beyond

2022 252 citations Lijuan Deng, Minfeng Chen et al. Molecular Cancer profile →

Peers

Countries citing papers authored by Wen-Yu Lyu

Since Specialization

Citations

This map shows the geographic impact of Wen-Yu Lyu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wen-Yu Lyu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wen-Yu Lyu more than expected).

Fields of papers citing papers by Wen-Yu Lyu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wen-Yu Lyu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wen-Yu Lyu. The network helps show where Wen-Yu Lyu may publish in the future.

Co-authorship network of co-authors of Wen-Yu Lyu

This figure shows the co-authorship network connecting the top 25 collaborators of Wen-Yu Lyu. A scholar is included among the top collaborators of Wen-Yu Lyu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wen-Yu Lyu. Wen-Yu Lyu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

#	Work	Indexed citations
1	Xerophenone H, a naturally-derived proteasome inhibitor, triggers apoptosis and paraptosis in lung cancer 2025 ·Phytomedicine ·Wen-Yu Lyu, Jun Cao, (unknown), Mu‐Yang Huang, Hongwei Guo, Ting Li, (unknown), Jin‐Jian Lu	1
2	Ginsenoside Rh2 in combination with IFNγ potentiated the anti-cancer effect by enhancing interferon signaling response in colorectal cancer cells 2025 ·Acta Pharmacologica Sinica ·(unknown), Chuncao Xu, Cheng Qian, Yanming Zhang, Wen-Yu Lyu, (unknown), Ting Li, Mingqing Huang, Jin‐Jian Lu	0
3	Polycyclic polyprenylated acylphloroglucinols from the pericarps of Garcinia multiflora champ. ex Benth. with cytotoxic property 2024 ·Phytochemistry ·Jun Cao, Wen-Yu Lyu, Yujia Zhang, Zhicheng Su, (unknown), Qingwen Zhang, Li‐She Gan, (unknown), Ligen Lin	1
4	Identification of Bulbocodin D and C as novel STAT3 inhibitors and their anticancer activities in lung cancer cells 2023 ·Chinese Journal of Natural Medicines ·Xinyu He, (unknown), Wen-Yu Lyu, Mu‐Yang Huang, Jianshan Mo, (unknown), (unknown), Lijun Zheng, (unknown), Lu Qi, Lele Zhang, (unknown), Mingqing Huang, Lin Ni, Jin‐Jian Lu	4
5	Targeting FAPα-positive lymph node metastatic tumor cells suppresses colorectal cancer metastasis 2023 ·Acta Pharmaceutica Sinica B ·(unknown), Ming Qi, Qi Qi, (unknown), Lijuan Deng, Jinghua Pan, Shenghui Qiu, (unknown), Maohua Huang, Zheng‐Xiang Li, (unknown), Jiapeng Lin, Wen-Yu Lyu, (unknown), (unknown), Xuesong Liu, (unknown), Dongmei Zhang, Wen‐Cai Ye, (unknown)	5
6	Erianin inhibits the growth and metastasis through autophagy-dependent ferroptosis in KRASG13D colorectal cancer 2023 ·Free Radical Biology and Medicine ·(unknown), (unknown), Wen-Yu Lyu, (unknown), (unknown), Ming Qi, Shenghui Qiu, (unknown), Jiapeng Lin, Minfeng Chen, Lijuan Deng	44
7	Identification of glycogen phosphorylase L as a potential target for lung cancer 2023 ·Medical Oncology ·(unknown), Wen-Yu Lyu, Xinyuan Li, Hong Zhao, Qi Lu, Jin‐Jian Lu	3
8	lncRNA SYTL5-OT4 promotes vessel co-option by inhibiting the autophagic degradation of ASCT2 2023 ·Drug Resistance Updates ·Qing Wen, Maohua Huang, Jingwen Xie, Runyu Liu, (unknown), (unknown), Junqiu Zhang, Wen-Yu Lyu, Ming Qi, Chun‐Yi Wu, Qi Qi, Zhijing Zhang, (unknown), Chenran Wang, Zhe‐Sheng Chen, Dongmei Zhang, Wen‐Cai Ye, (unknown)	9
9	Ginsenoside Rh2 augmented anti-PD-L1 immunotherapy by reinvigorating CD8+ T cells via increasing intratumoral CXCL10 2023 ·Pharmacological Research ·Mu‐Yang Huang, Yu‐Chi Chen, Wen-Yu Lyu, Xinyu He, (unknown), (unknown), (unknown), Xiuping Chen, Xiaobing Chen, (unknown), Guoyin Kai, Xiaolei Zhang, Ting Li, (unknown), (unknown), Jin‐Jian Lu	37
10	m6A modification: recent advances, anticancer targeted drug discovery and beyond breakdown → 2022 ·Molecular Cancer ·Lijuan Deng, (unknown), (unknown), Minfeng Chen, Ming Qi, Wen-Yu Lyu, Qi Qi, Amit K. Tiwari, Jiaxu Chen, Dongmei Zhang, Zhe‐Sheng Chen	252
11	Evodiamine as the Active Compound of Evodiae fructus to Inhibit Proliferation and Migration of Prostate Cancer through PI3K/AKT/NF-κB Signaling Pathway 2022 ·Disease Markers ·Yuhe Lei, (unknown), Haiyan Liu, Wen-Yu Lyu, Lei Chen, (unknown), (unknown), Mei Wang, Ming Qi, Yu Guo, Junshan Liu, Enxin Zhang	17
12	Notoginsenoside R1 activates the Ang2/Tie2 pathway to promote angiogenesis 2020 ·Phytomedicine ·Jincheng Zhong, (unknown), Jiayan Zhang, Maohua Huang, Wen-Yu Lyu, (unknown), Lijuan Deng, (unknown), Nan Yao, Yong Li, (unknown), Yunfei Liang, (unknown), Dongmei Zhang, Wen‐Cai Ye	27
13	Natural products as potent inhibitors of hypoxia-inducible factor-1α in cancer therapy 2020 ·Chinese Journal of Natural Medicines ·Jincheng Zhong, Xiaobo Li, Wen-Yu Lyu, Wen‐Cai Ye, Dongmei Zhang	16

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact